



Dkt. 58075-Z/JPW/GJG/JAS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Ridwan Shabsigh  
U.S. Serial No.: 10/658,991 Examiner: Robert M. Kelly  
Filing Date : September 9, 2003 Group Art Unit: 1633  
For : USES OF VASCULAR ENDOTHELIAL GROWTH FACTOR  
IN THE TREATMENT OF ERECTILE DYSFUNCTION

1185 Avenue of the Americas  
New York, New York 10036  
April 20, 2007

MAIL STOP RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

**AMENDMENT IN RESPONSE TO SEPTEMBER 13, 2006 FINAL OFFICE ACTION  
AS A SUBMISSION UNDER 37 C.F.R. § 1.114(c)  
ACCOMPANYING A REQUEST FOR CONTINUED EXAMINATION (RCE)**

This Amendment is submitted in response to the September 13, 2006 Final Office Action issued by the U.S. Patent and Trademark Office in connection with the above-identified application. Applicants are concurrently submitting a Request for Continued Examination (RCE). Accordingly, this Amendment is to be treated as a submission under 37 C.F.R. § 1.114(c) accompanying an RCE. A response to the September 13, 2006 Final Office Action was due December 13, 2006. On February 13, 2007, Applicants filed a Notice of Appeal from the Examiner's Decision to the Board of Patent Appeals and Interferences and Petition for Two-Month Extension of Time, including a check in the amount of four hundred and seventy-five dollars. The Notice of Appeal was received in the Patent and Trademark Office on February 20, 2007, setting the deadline for taking further action as April

Applicants: Ridwan Shabsigh  
Serial No.: 10/658,991  
Filed: September 9, 2003  
Page 2

20, 2007. Accordingly, this RCE and accompanying submission under 37 C.F.R. § 1.114(c) are considered timely.

Please amend the subject application as follows:

**Amendments to the claims** begin on page 3 of this paper.

**Remarks** begin on page 6 of this paper.